New trial
Phase 1 Trial of miRisten, a cell growth molecule blocker, for relapsed/refractory AML
- Trial ID
- NCT07025564 on ClinicalTrials.gov
- Cancer type
- Acute Myeloid Leukemia
- Stage of research
- First-in-human
- Published in
- New in Oncology - July 3, 2025
This Phase 1 trial at City of Hope Medical Center evaluates miRisten administered via IV infusion on a multi-day schedule to determine its safety, tolerability, and optimal dosing in adult patients with relapsed/refractory AML. Detailed cardiac assessments and biomarker sampling aim to clarify its mechanism and clinical potential.
More in acute myeloid leukemia and MDS
-
Trial result · Oct 22, 2026 · NCT03672539
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML -
New trial · Oct 15, 2026 · NCT07809906
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies -
Trial result · Sep 17, 2026 · NCT02159495
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity -
New trial · Sep 10, 2026 · NCT07581002
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML -
New trial · Sep 10, 2026 · NCT07780565
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS